Solstice
It builds AI-native marketing software for pharmaceutical companies to accelerate drug campaign development from months to days.
Overview
Solstice is an AI-native pharma marketing startup focused on shortening the time required to build drug campaigns. Its offering targets pharmaceutical commercial and marketing teams seeking to move campaign development from traditional multi-month timelines to faster AI-assisted workflows. The company’s stated differentiator is speed: it aims to cut drug campaign timelines from about three months to 10 days. Solstice raised $21 million in an undisclosed round announced in May 2026, bringing total disclosed funding to $21 million.
Funding History
AI-native pharma marketing startup Solstice raises $21M to cut drug campaign timelines from 3 months to 10 days
Frequently Asked Questions
- How much has Solstice raised in total?
- Solstice has raised a total of $21M across 1 funding round.
- Who are Solstice's investors?
- Solstice's investors include Undisclosed.
- What does Solstice do?
- Solstice is an AI-native pharma marketing startup focused on shortening the time required to build drug campaigns. Its offering targets pharmaceutical commercial and marketing teams seeking to move campaign development from traditional multi-month timelines to faster AI-assisted workflows. The company’s stated differentiator is speed: it aims to cut drug campaign timelines from about three months to 10 days. Solstice raised $21 million in an undisclosed round announced in May 2026, bringing total disclosed funding to $21 million.
- Where is Solstice headquartered?
- Solstice is headquartered in San Francisco, CA.
Investors
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.